Q32 Bio Inc.

NASDAQ:QTTB

Biotechnology

Healthcare
$8.53 -1.70%

-$0.22 today

Market cap
$255.25M
Beta
-0.23
P/E (TTM)
5.4
EPS (TTM)
$2.36
52W Low $1.35High $14.85

Volume 0.26M

Average 0.74M

QTTB Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Q32 Bio Inc.NASDAQ: QTTB

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q1 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $53.74M. Over 3 fiscal years it compounded at +100.7% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 5 analysts of $285.71K (-99.5%) for the fiscal year ending Dec 2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$53.74M— YoY
LTMMar 2026
$53.74M— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year—-99.5%—
3-year CAGR+100.7%-64.0%-164.7 pp
5-year CAGR+23.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
53.74M USD
Year-over-year change
—
4-year CAGR
+12.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How QTTB compares with its peers on the latest reported figures

  • QTTB's LTM Mar 2026 revenue of $53.74M is the highest of the 5 companies compared; the peer median is $0.
  • Over three fiscal years its annual growth of +100.7% compares with a peer median of +57.9%.
QTTB Competitors Peer median
Revenue for QTTB and competitors
Company Period LTM YoY 3-year CAGR
QTTBQ32 Bio Inc.LTM Mar 2026$53.74M —+100.7%
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026$37.16M +417.6%+57.9%
SABSSAB Biotherapeutics, Inc.LTM Jun 2026$0 -100.0%—
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$0 ——
BOLDBoundless Bio, Inc.LTM Mar 2026$0 ——
Peer median (excluding QTTB) $0+158.8%+57.9%

Competitors are the stored peer set for QTTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue33.97M6.65M(6.65M)053.74M
Cost of Revenue9.54M2.6M499K487K391K
Gross Profit24.43M6.65M(6.65M)(487K)53.35M
Gross Margin71.9%100.0%100.0%—99.3%
Research & Development93.09M35.81M31.73M48.14M19.16M
Selling, General & Admin27.29M10.06M9.88M17.47M17.68M
Operating Expenses120.38M45.88M41.6M65.61M36.44M
Depreciation & Amortization9.54M370K499K487K391K
EBITDA(86.22M)(38.86M)(47.76M)(45.3M)17.29M
EBITDA Margin-253.8%-584.2%718.0%—32.2%
Operating Income(95.95M)(39.23M)(48.26M)(66.1M)16.9M
Operating Margin-282.4%-589.8%725.5%—31.5%
Interest Income185K3.23M03.9M2.2M
Interest Expense000300K1.1M
Other Income / Expenses185K(3.52M)(5.17M)18.39M12.92M
Income Before Tax(95.76M)(42.75M)(53.43M)(47.71M)29.82M
Pre-Tax Margin-281.9%-642.7%803.3%—55.5%
Income Tax Expense062K318K21K0
Net Income(95.76M)(42.81M)(53.74M)(47.73M)29.82M
Net Margin-281.9%-643.6%808.0%—55.5%
EPS (Basic)(31.18)(13.42)(16.70)(5.12)2.42
EPS (Diluted)(31.18)(13.42)(16.70)(6.58)2.42
Weighted Avg Shares3.07M3.19M3.22M12.2M12.3M
Weighted Avg Shares (Diluted)3.07M3.19M3.22M12.2M12.31M

Q32 Bio Inc.

NASDAQ:QTTB

Intrinsic Alpha fair value

Locked

Current Price

$8.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.